Advanced Search

 

Study ID Status Title Patient Level Data
APV10015 Completed A Pivotal, Phase I, Single-dose, Open-label, Randomized, Three Period, Balanced Crossover Study to Assess the Bioequivalence of GW433908 Oral Film-coated 700mg Tablet Formulations in Healthy Adult Subjects
APV10016 Completed A Pivotal, Phase I, Single-dose, Open-label, Randomized, Four Period, Balanced Crossover Study to Assess the Relative Bioavailability of the GW433908 Oral Suspension and Oral Film-coated 700mg Tablet Formulations and the Effect of Food on the Bioavailability of These Formulations in Healthy Adul ...
APV10017 Completed See Detailed Description
APV10018 Completed A Phase I, Randomized, Open Label, Four Arm, Two Period, Two 2x2, Crossover, Drug Interaction Study to Assess Steady-State Plasma Amprenavir and Atazanavir Pharmacokinetics following Administration of Fosamprenavir 700mg BID + Ritonovir 100mg BID + Atazanavir 300mg QD, Fosamprenavir 700mg BID + ...
APV10020 Completed A Phase I, Open Label, Two Period, Single-Sequence, Drug-Drug Interaction Study Comparing Steady-State Plasma Ethinyl Estradiol and Norethisterone Pharmacokinetics following Administration of Brevinor for 21 Days with and without Fosamprenavir 700 mg Twice Daily (BID) and Ritonavir 100 mg BID fo ...
APV10021 Completed A Pivotal, Phase I, Single-dose, Open-label, Randomized, Two-Period, Balanced Crossover Study to Assess the Bioequivalence of GW433908 Oral Film-coated 700mg Tablets in Healthy Adult Subjects
APV10022 Completed A Phase I, Randomized, Open Label, Two-Period, Four-Arm, Balanced Cross-over, Steady-state, Drug Interaction Study between Ritonavir 100mg BID and FPV 700mg BID and between Ritonavir 100mg BID and AGENERASE† 600mg BID in Healthy Adult Subjects
APV10023 Completed A Pivotal, Phase I, Open-label, Randomized, Four-Period, Single and Multiple Dose, Crossover Study to Assess the Bioequivalence of Two GW433908 700mg Oral Film-coated Tablet Variants Following Administration of Single 1400mg Doses and Following Administration of 1400mg BID for 14 Days…
APV10024 Completed A Pivotal, Phase I, Open-label, Randomized, Four-Period, Two-Part, Crossover Study to Assess the Relative Bioavailability of the Fosamprenavir 50mg/mL Oral Suspension and 700mg Oral Film-coated Tablet Formulations Following Administration of Single 1400mg Doses and Following Administration of 14 ...
APV10025 Completed A Phase I, Randomized, Open Label, Two Period, Two Sequence, Drug-Drug Interaction Study Comparing Steady-State Plasma Rifabutin Pharmacokinetics following Coadministration of Fosamprenavir 700mg + Ritonavir 100mg Twice Daily (BID) and Rifabutin 150mg Every Other Day (QOD) and following Administ ...
APV10026 Completed A Phase I, Open-Label, Single-Sequence, Drug-Drug Interaction Study Comparing Ketoconazole and Amprenavir Pharmacokinetics Following Administration of Ketoconazole 200 mg QD for Four Days, Fosamprenavir 700mg BID + Ritonavir 100mg BID for Ten Days, and Ketoconazole 200 mg QD + Fosamprenavir 700m ...
APV10028 Completed A Phase I, Open, Randomized, Balanced, Three-Period, Crossover, Steady-State, Pharmacokinetic Study Comparing GW433908 1400mg BID + RTV 100mg BID, GW433908 1400mg BID + RTV 200mg BID, and GW433908 700mg BID + RTV 100mg BID Regimens in Healthy Adult Subjects
APV10029 Completed A Phase I, Open-label, Randomized, Two-Period, Balanced Crossover, Study to Compare Steady-State Plasma Amprenavir Pharmacokinetics following administration of Two GW433908 Tablet Variants, Each administered as 1400mg QD in Combination with Ritonavir 200mg QD in Healthy Adult Subjects
APV10031 Completed A Phase I, Randomized, Open Label, Two Arm, Three Period, Drug-Drug Interaction Study Comparing Steady-State Plasma Amprenavir and Esomeprazole Pharmacokinetics following Coadministration of GW433908 1400mg BID and Esomeprazole 20mg QD and following Coadministration of GW433908 700mg BID + RTV 1 ...
APV102002 Completed A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological Failure
APV109141 Completed Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.
APV20001 Completed Open-Label Phase Report of: A Randomized, Multicenter, Partially Double-Blinded, Repeat Dose, Cross-Over Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Effect of Two Doses of FPV Compared with AGENERASE(1200mg BID) when Given for 28 Days to Subjects Infected with HIV-1
APV20002 Active not recruiting A 48 week, Phase II, open-label, 2-cohort, multicenter study to evaluate the pharmacokinetics, safety, tolerability and antiviral activity of GW433908 and GW433908/RTV when administered to HIV-1 infected protease inhibitor (PI) naive and PI-experienced pediatric subjects aged 4 weeks to <2 years.
APV29005 Completed See Detailed Description
APV30001 Completed A Phase III, Randomized, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety and Tolerability of GW433908 (1400mg BID) and Nelfinavir (1250mg BID) Over 48 Weeks in Antiretroviral Therapy-Naïve HIV-1 Infected Adults
APV30002 Completed A Randomized, Open-Label, Two Arm Trial to Compare the Safety and Antiviral Efficacy of GW433908/Ritonavir QD to Nelfinavir BID When Used in Combination with Abacavir and Lamivudine BID for 48 Weeks in Antiretroviral Therapy Naïve HIV-1 Infected Subjects
APV30003 Completed A Phase III, Randomized, Multicenter, Parallel Group, Open-label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/ritonavir (700mg/100mg twice daily or 1400mg/200mg once daily) versus lopinavir/ritonavir (400mg/100mg twice daily) for 48 Weeks in Protease Inh ...
APV30005 Completed An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects
APV30007 Completed A 24 week Phase IIIb/IV single arm open label observational study to explore the efficacy of protease inhibitors given in combination with reverse transcriptase inhibitors to HIV-1 infected subjects with protease mutations selected during therapy with GW433908 containing antiretroviral therapy
APV40003 Completed Safety and efficacy of GW433908 in antiretroviral combination therapy in patients with HIV infection

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.